trial

Treatment of N-methyl-D-aspartate (NMDA) Enhancers for Schizophrenia

NCTId NCT01047592
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 63 (actual)
Sponsored by Chang-Hua Hospital
Primary completion 2013-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
63 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2009-03
Primary completion
2013-12
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Sarcosine

Sponsors

Chang-Hua HospitalLead Sponsor
China Medical University HospitalCollaborator

Investigators

2
Chun-yuan Lin, MDPrincipal Investigator
Hsien-Yuan Lane, MD.PhD.Study Director

Sites

1 total
Changhua, Taiwan

Linked catalysts

1
Treatment of N-methyl-D-aspartate (NMDA) Enhancers for Schizophrenia — primary completion2013-12

Facts & assertions

4 sourced
Enrollment
63
Phase
PHASE2
Primary Completion Date
2013-12
Status
COMPLETED
relationships
The graph out of here
drug
Sarcosine
drug
lead_sponsor
Chang-Hua Hospital
company
collaborator
China Medical University Hospital
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Chun-yuan Lin, MD
person
Hsien-Yuan Lane, MD.PhD.
person